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Abstract
Background: The role of endothelial dysregulation with acute kidney injury (AKI) in critically ill patients is unclear.
Methods: We retrospectively assessed the associations of AKI with biomarkers of endothelial function and
inflammation among 948 subjects admitted to the intensive care unit (ICU) at Harborview Medical Center
(Seattle, WA, USA). From plasma obtained within 24 h of enrollment, we measured angiopoietin (Ang)-1 and
Ang-2 alongside biomarkers of inflammation, including interleukin (IL)-6, IL-17 and granulocyte colony-stimulating
factor. We tested for associations between standardized concentrations of biomarkers and AKI, defined by serum
creatinine, from ICU admission to up to 7 days later.
Results: All biomarkers of inflammation and endothelial dysfunction were associated with AKI. After adjustment
for demographics, comorbidities, and IL-6 concentration, every standard deviation of Ang-1 concentration was
associated with a 19 % lower risk of AKI (relative risk (RR) = 0.85, 95 % confidence interval (CI) 0.77–0.93, p < 0.001).
Conversely, higher Ang-2 concentration was associated with higher risk of AKI (RR per standard deviation = 1.17,
95 % CI 1.13–1.22, p < 0.001).
Conclusions: In critically ill patients, plasma concentration of the endothelial growth factors Ang-1 and Ang-2 are
associated with AKI, independently of inflammation.
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Background
Acute kidney injury (AKI) is a common complication of
sepsis and the systemic inflammatory response syn-
drome (SIRS), and is highly associated with prolonged
hospitalization, dialysis requirement, and sepsis-related
death in critically ill patients [1–7]. AKI is defined as an
abrupt (within 48 h) reduction in kidney function based
on an elevation in serum creatinine level, a reduction in
urine output, the need for renal replacement therapy
(dialysis), or a combination of these factors. Unfortunately,
serum creatinine is a lagging indicator of the early struc-
tural damage of AKI, rising well after the functional
change in glomerular filtration rate [8–10]. This makes it
difficult to prospectively identify patients at risk for severe
forms of AKI and related outcomes. Novel sensitive and
specific biomarkers are urgently needed to provide for
cost-effective and non-invasive methods to identify those
at risk for severe AKI.
For many years, neutrophil gelatinase-associated lipoca-
lin (NGAL) was considered the most promising biomarker
of AKI [11–13]. However, in the setting of critical illness
its use has been hampered by a confounding lack of speci-
ficity, as the inflammatory response in sepsis causes in-
creased synthesis of NGAL in the lungs and liver,
irrespective of kidney damage [10, 14–16]. Thus, NGAL
may not be a useful AKI marker in patient populations
where the noise from severe systemic inflammation and
multi-organ damage is so pronounced.
While the pathogenesis of AKI in critically ill patients
is complex, insights into the mechanisms underlying its
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course may uncover novel biomarkers. Historically, se-
vere systemic inflammation—that is, elevated circulating
levels of tumor necrosis factor (TNF), interleukin (IL)-6,
granulocyte colony-stimulating factor (G-CSF) and other
inflammatory mediators—was thought to play the major
role in sepsis-induced organ dysfunction [17–20].
However, more recently, endothelial cell activation and
subsequent vascular barrier breakdown have emerged as a
critical pathogenic mechanism in organ damage [21–23].
While the exact pathogenesis of AKI in this context
remains unclear, recent evidence suggests an important
role for microvascular endothelial injury and dysfunction
in epithelial cell injury during ischemic AKI, especially
during the reperfusion phase [9, 24].
Angiopoietins (Ang) are angiogenic factors essential
for vascular development, maturation, and inflammation.
Ang-1 and its context-dependent antagonist Ang-2 are
secreted endothelial growth factors which bind to the
extracellular domain of the tyrosine kinase receptor
Tie2 that is predominantly expressed on endothelial
cells. Ang-1 can be protective, with a role in stabilizing
endothelium, while Ang-2, which promotes vascular leak,
can worsen outcomes in sepsis [25–28]. With activation
of the endothelium, luminal adhesion molecules are
upregulated, including soluble vascular cell adhesion
molecule-1 (sVCAM-1) [29].
Biomarkers of endothelial injury and dysfunction have
been implicated in the development of poor outcomes in
diseases with systemic inflammation [30–32]. However,
the clinical significance of endothelial markers in the
setting of AKI has not yet been clarified.
Methods
Study population
The Harborview Medical Center (Seattle, WA, USA)
SIRS cohort includes patients admitted to the intensive
care unit (ICU) for more than 24 h and with at least two
of four SIRS criteria [33, 34]. Exclusion criteria include
admission for major trauma, intracranial hemorrhage,
HIV, immunosuppression, or a current diagnosis of
cancer. All subjects have associated plasma specimens
obtained within 24 h of admission to the ICU, and were
followed until hospital discharge or death. The institu-
tional review board of the University of Washington ap-
proved the protocols for recruitment and sample
collection, which was performed with informed consent
of the participants.
Biomarker measurement
Plasma samples were thawed and concentrations of IL-6,
IL-8, G-CSF, tumor necrosis factor receptor-1 (TNFR-1),
Ang-1, Ang-2, and sVCAM-1 were all measured on the
same day using electrochemiluminescent immunoassays
(Meso Scale Discovery, Rockville, MD, USA). Samples
were diluted to fit within the dynamic range of the
assay, defined as the following: 0.08–2500 pg/mL for IL-6,
IL-8, and TNFR-1; 0.12–5000 pg/mL for G-CSF; 3–
100,000 pg/mL for Ang-1; 0.5–10,000 pg/mL for Ang-2;
and 0.05–1000 pg/mL for sVCAM-1. The samples that fell
below the lower or upper limits of detection were assigned
those values. Missingness (~5 %) in certain biomarker
concentrations was due to insufficient sample volumes in
a small subset of subjects.
Acute kidney injury
Serum creatinine was determined daily for the duration
of the hospital stay as part of routine patient care. AKI
status was determined by changes in serum creatinine in
accordance with the Kidney Disease Improving Global
Outcomes (KDIGO) criteria for AKI [35], from ICU
admission to up to 7 days later. AKI was defined as any
increase in serum creatinine by 0.3 mg/dL within 48 h
or an increase in serum creatinine by 1.5-fold within
7 days. Severe AKI was defined as KDIGO stages 2 or 3.
Because this study was not designed with AKI as a pri-
mary endpoint, hourly urine output and renal replace-
ment therapy data were not available to provide enough
granularity to the severity of AKI definition.
Covariates
Admission data, hospital course, and complications were
obtained from the electronic medical record. The APA-
CHE (Acute Physiology, Age, Chronic Evaluation) III
prognostic score and the Sequential Organ Failure As-
sessment (SOFA) were calculated as previously described
[36, 37]. Baseline serum creatinine was defined as cre-
atinine at admission, and chronic kidney disease (CKD)
status was defined as a glomerular filtration rate below
60 mL/min/1.73 m2 as estimated using the creatinine-
based CKD-EPI equation [38].
Statistical analyses
Baseline descriptive statistics on demographics, medical
history, and admission characteristics were examined by
AKI stage. We report continuous variables as means ±
standard deviations and categorical variables as numbers
and percentages.
Plasma biomarker concentrations were tabulated by
AKI stage and reported as median and interquartile
range. P values were obtained using Wald tests on the
grouped linear AKI stage term regressed on the log-base
transformed biomarker concentration.
Pearson’s correlation coefficient (ρ) was used to esti-
mate the magnitude of the linear correlation between
log-transformed biomarker concentrations.
For associations of biomarkers with the risk of AKI,
we first defined our outcome as AKI of any stage and
secondarily examined associations of biomarkers with
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severe AKI, to increase specificity of the outcome defin-
ition. Relative risk regression was used to model the
probability of AKI as a function of covariates using a
generalized linear model with log link and binomial
error distribution [39]. In cases in which the model
failed to converge with the binomial error (~10 % of the
models), we substituted Gaussian error and used robust
standard error estimates. We used relative risk regression
rather than logistic regression because the prevalence of
AKI is not rare (occurring in >22 % of participants during
hospitalization), hence the odds ratio is an overestimate of
the relative risk.
Univariate and multivariable associations of biomarker
concentrations with AKI were presented as relative risks
(RRs) per standard deviation of the biomarker. The first
adjustment model included baseline age, gender, admitting
service (medical, surgical), body mass index, smoking sta-
tus, prevalent diabetes, chronic renal insufficiency, and
cirrhosis. Subsequent models added variables to the basic
adjustment model that may possibly confound or mediate
the associations of interest. The second model added
the APACHE III score, and the final model added log-
transformed circulating IL-6 concentrations.
We performed a secondary analysis to evaluate tem-
porality issues and the potential of reverse causality,
in which we repeated examination of the association
of biomarkers with the AKI endpoint after exclusion
of patients with AKI events occurring within the first
24 h of admission.
We evaluated the significance of all 32 two-way multi-
plicative interactions among biomarkers using the Wald
test with a Bonferroni-corrected two-tailed α = 0.0016
(0.05/32). All other p values were two-tailed (α = 0.05)
and all analyses were performed using Stata release 13.1
(College Station, TX, USA).
Results
At baseline, the mean age was 55 years and 36 % of pa-
tients were women. Of the 948 patients admitted, 506
(53 %) experienced an AKI event, according to KDIGO
criteria. As expected, patients with AKI of higher stages
were more likely to have higher APACHE III scores and
higher SOFA scores, and were more likely to have been
admitted to the ICU from a medical source (Table 1).
Measured concentrations of all plasma biomarkers
were associated with AKI stage (all p < 0.0025). Patients
with higher stages of AKI had higher median concentra-
tions of the inflammatory biomarkers IL-6, IL-8, IL-17,
G-CSF, and TNFR-1, higher median concentrations of
the endothelial biomarkers Ang-2, the Ang-2/Ang-1
Table 1 Baseline characteristics by AKI stage
Variable No AKI AKI stage 1 AKI stage 2 AKI stage 3
N 442 376 17 113
Age, years 55.0 (16.8) 56.8 (16.0) 47.6 (18.0) 53.0 (15.0)
BMI, kg/m2 28.1 (18) 32.0 (18.3) 30 (6.3) 32.4 (11.8)
Creatinine, mg/dL 0.86 (0.39) 1.14 (0.53) 0.74 (0.22) 3.74 (3.08)
SOFA score 3 (2.5) 4.7 (2.8) 3.8 (2.7) 7.5 (3.2)
APACHE III 42.2 (24.3) 55.1 (27) 53.6 (16.5) 66.5 (34.8)
Caucasian 442 (100) 376 (100) 17 (100) 113 (100)
Female gender 176 (39.8) 119 (31.7) 8 (47.1) 41 (36.3)
Source of ICU admission
Medical 228 (51.6) 200 (53.2) 8 (47.1) 83 (73.5)
Surgical 214 (48.4) 176 (46.8) 9 (52.9) 30 (26.6)
Death within 28 days 14 (3.2) 63 (16.8) 3 (17.7) 31 (27.4)
Comorbidities
Chronic kidney disease 12 (2.7) 34 (9.0) 0 (0) 20 (17.7)
Diabetes mellitus 86 (19.5) 111 (29.5) 7 (41.2) 30 (26.6)
Cirrhosis 36 (8.1) 35 (9.3) 3 (17.7) 10 (8.9)
Current smoking 264 (59.7) 205 (54.5) 9 (52.9) 62 (54.9)
Source of critical illness
Pneumonia 85 (19.2) 87 (23.1) 5 (29.4) 17 (15.0)
Sepsis 269 (60.9) 269 (71.5) 14 (82.4) 80 (70.8)
Other 74 (16.7) 79 (21.0) 3 (17.7) 21 (18.6)
AKI acute lung injury, APACHE Acute Physiology, Age, Chronic Evaluation, BMI body mass index, ICU intensive care unit, SOFA Sequential Organ Failure Assessment
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ratio, and sVCAM-1, and lower median concentrations
of Ang-1 (Table 2, Fig. 1).
There were moderate correlations between and among
the endothelial biomarkers and inflammatory bio-
markers. (Additional file 1). The strongest correlations
between inflammatory and endothelial biomarkers were
observed for Ang-2 and TNFR-1 (ρ = 0.60) and for Ang-
2 and IL-6 (ρ = 0.49).
After adjustment for demographics, lifestyle character-
istics, and comorbidities, higher concentrations of all
biomarkers were associated with the adjusted risk of
AKI of any stage during hospitalization. Specifically,
every standard deviation higher concentration of Ang-1
was associated with an estimated 19 % lower adjusted
risk of AKI (95 % confidence interval (CI): 11 % lower to
33 % lower, p < 0.001; Table 3) and every standard devi-
ation higher concentration of Ang-2 was associated with
an estimated 22 % higher risk of AKI (95 % CI: 18 %
higher to 26 % higher, p < 0.001; Table 3).
Similarly, higher concentrations of all endothelial and
inflammatory biomarkers were associated with the risk
of stage 2–3 AKI during hospitalization. Specifically,
every standard deviation higher concentration of Ang-1
was associated with an estimated 50 % lower adjusted risk
of stage 2–3 AKI (95 % CI: 33 % lower to 67 % lower,
p = 0.002; Additional file 2) and every standard deviation
higher concentration of Ang-2 was associated with an esti-
mated 59 % higher risk of stage 2–3 AKI (95 % CI: 48 %
higher to 72 % higher, p < 0.001; Additional file 2). Associ-
ations of endothelial biomarkers with risk of stage 2–3
AKI were robust to adjustment for the APACHE III score
and for circulating IL-6.
In sensitivity analyses that excluded 173 participants
with AKI events within the first 24 h of admission,
associations were similar and more robustly similar for
the endothelial biomarkers (Additional file 3). Significant
two-way interactions (p < 0.001) among the biomarkers
in association with AKI events were observed for the
Ang-2/Ang-1 ratio and IL-17, VCAM, Ang-2, and G-
CSF, and for sVCAM with TNFR-1 and Ang-2, and for
Ang-2 with TNFR-1. In a multivariable model with ad-
justment for all inflammatory markers and Model 1 co-
variates, IL-6 and TNFR-1 each remained associated
with the risk of AKI. In a multivariable model with ad-
justment for all endothelial markers and Model 1 covari-
ates, Ang-1 and Ang-2 each remained associated with
the risk of AKI.
Discussion
This study is the first to report associations of endothelial
biomarkers with AKI in a large general medical/surgical
ICU population. The results observed are consistent with
previous studies, which have shown inflammatory markers
to be associated with AKI events in various critically ill
populations [40]. Several relatively smaller studies have
recently explored associations of endothelial biomarkers
and AKI. Recent case-control studies of cardiac surgery
patients have found that plasma levels of Ang-2 increase
post-surgically by a greater extent in patients who develop
AKI than in controls [41, 42]. A cross-sectional study of
critically ill patients at inception of renal replacement
therapy in the ICU found that circulating Ang-2 was
correlated with AKI stage and with 28-day mortality
risk [43].
Accumulating evidence suggests that systemic inflam-
mation and endothelial activation underlie the develop-
ment of AKI [41, 43–46]. TNF is an inflammatory
marker released by activated macrophages, monocytes,
Table 2 Plasma biomarkers according to AKI stage
Biomarker
concentration
N No AKI AKI KDIGO stage
Stage 1 Stage 2 Stage 3
Median (IQR) Median (IQR) Median (IQR) Median (IQR) p-value
Endothelial
Ang-1, pg/mL 935 6487.3 (3160.7–10,867.1) 4424.7 (2084.6–8424.4) 4393.3 (3458.2–13,075.6) 3209.9 (1481.1, 6574.4) <0.0001
Ang-2, pg/mL 944 9535.4 (5740.2–17,154.9) 16283.0 (8491.6–32,757.3) 16149.8 (9764.0–22,833.7) 31227.4 (17316.6, 67176.1) <0.0001
Ang-2/Ang-1 935 1.4 (0.65–4.3) 3.9 (1.8–13.3) 2.7 (1.1–7.6) 9.4 (3.7, 34.6) <0.0001
sVCAM-1, ng/mL 944 497.4 (402.9–699.2) 569.9 (446.2–803.2) 708.6 (485.5–1058.6) 828.6 (601.5, 1249.9) <0.0001
Inflammatory
IL-6, pg/mL 891 99.8 (46.5–233.4) 151.4 (63.6–420.1) 174.5 (82.3–461.5) 171.8 (102.2, 400.9) <0.0001
IL-8, pg/mL 891 11.0 (6.1–22.6) 14.8 (7.7–35.0) 16.4 (9.0–32.6) 22.8 (11.4, 51.0) <0.0001
IL-17, pg/mL 853 2.5 (1.1–7.2) 3.8 (1.4–9.7) 6.8 (1.7–11.6) 4.6 (1.7, 12.1) 0.0001
G-CSF, pg/mL 891 24.1 (14.2–45.8) 30.3 (17.2–72.6) 31.7 (17.6–66.9) 31.3 (18.2, 70.6) 0.0025
TNFR-1, pg/mL 891 6281.3 (4565.8–9790.6) 9952.6 (6411.5–14,879.7) 8910.5 (5198.26–19,151.48) 31474.3 (18514.3, 47995.3) <0.0001
AKI acute lung injury, Ang angiopoietin, G-CSF granulocyte colony-stimulating factor, IL interleukin, IQR interquartile range, KDIGO Kidney Disease Improving Global
Outcomes, TNFR-1 tumor necrosis factor receptor 1, sVCAM-1 soluble vascular cell adhesion molecule-1
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Fig. 1 Distribution of acute kidney injury (AKI) cases by biomarker concentration. Bar chart displays the percentage of participants within each
biomarker concentration quartile that developed AKI of any stage. Below the bar chart, the number of participants within each biomarker quartile
is broken down into case status for AKI and, among those with AKI, into KDIGO AKI stage. Ang angiopoietin, S-VCAM-1 soluble vascular cell
adhesion molecule-1










Ang-1 0.81 (0.74–0.88)*** 0.81 (0.73–0.89)*** 0.87 (0.80–0.95)** 0.85 (0.77–0.93)***
Ang-2 1.22 (1.19–1.25)*** 1.22 (1.18–1.26)*** 1.16 (1.11–1.20)*** 1.17 (1.13–1.22)***
Ang-2/Ang-1 1.06 (1.03–1.08)*** 1.06 (1.03–1.08)*** 1.04 (1.02–1.06)*** 1.05 (1.03–1.07)***
sVCAM-1 1.09 (1.07–1.12)*** 1.17 (1.12–1.21)*** 1.13 (1.07–1.18)*** 1.14 (1.10–1.19)***
Inflammatory
IL-6 1.10 (1.07–1.14)*** 1.10 (1.06–1.14)*** 1.04 (1.00–1.08) –
IL-8 1.04 (1.01–1.07)* 1.04 (1.02–1.07)** 1.01 (0.98–1.03) 1.01 (0.98–1.04)
IL-17 1.07 (1.05–1.10)*** 1.06 (1.03–1.09)*** 1.05 (1.02–1.08)** 1.04 (1.00–1.07)*
G-CSF 1.06 (1.03–1.10)** 1.06 (1.03–1.10)** 1.01 (0.97–1.06) 0.99 (0.95–1.04)
TNFR-1 1.21 (1.18–1.23)*** 1.20 (1.17–1.22)*** 1.16 (1.14–1.19)*** 1.17 (1.15–1.20)***
Relative risks (RR) presented per standard deviation of each biomarker
aRelative risk regression adjusted for age, gender, sepsis, admitting service (ex: medical = 1, surgical = 0), body mass index, smoking status, diabetes mellitus,
chronic renal insufficiency, and cirrhosis
bAdjusted for APACHE III and covariates in a
cAdjusted for Log2 (IL-6) concentration and covariates in
a
*p < 0.05; **p < 0.01; ***p < 0.001
Ang angiopoietin, APACHE Acute Physiology, Age, Chronic Evaluation, CI confidence interval, G-CSF granulocyte colony-stimulating factor, IL interleukin, TNFR-1
tumor necrosis factor receptor 1, sVCAM-1 soluble vascular cell adhesion molecule-1
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and neutrophils, and has been shown to have a major
role in both sepsis and septic AKI [20, 47–49]. Renal
endothelial cells are activated by TNF, further perpetuating
the pro-inflammatory state and potentially sensitizing
kidney tissue to subsequent damage [47, 48]. Recent
efforts in animal models have demonstrated that Ang-1
may enhance the protective capacity of early endothelial
outgrowth cells in murine AKI [50, 51]. Acute endothelial
cell changes may lead to altered vascular reactivity, perme-
ability, adherence of leukocytes, coagulation, and micro-
vascular vasomotor autoregulation, perpetuating AKI.
Among a large cohort of critically ill patients admitted
to the ICU, we found that circulating concentrations of
inflammatory and endothelial biomarkers were signifi-
cantly associated with a higher risk of AKI.
These biomarkers may highlight novel pathways of
kidney injury in the setting of critical illness as well as
the potential use of baseline biomarker profiles to iden-
tify individuals at risk of developing AKI. Our observa-
tions support the hypothesis that, before overt renal
cellular injury has occurred, there may be alterations in
microcirculation and tissue oxygenation that predispose
individuals to renal damage [52]. This concept is especially
relevant to the SIRS state, where inflammation and endo-
thelial cell activation are prominent [16]. The microvascu-
lature and endothelial cells in particular regulate blood
flow to local tissue beds and modulate coagulation, in-
flammation, and vascular permeability. AKI has profound
effects on the renal endothelium, resulting in microvascu-
lar dysfunction leading to ongoing ischemic conditions
and further injury following the initial insult [53, 54].
While we highlight, for the first time, the independent
association of endothelial biomarkers with AKI in critic-
ally ill patients, our study has some limitations. The
most important limitation of this observational study is
the potential for confounding, because characteristics
such as illness severity are likely linked both with endo-
thelial dysregulation and risk of AKI. Substantial efforts
were made to adjust for potential confounding, but a
causal association between the dysfunction of endothe-
lial cells and AKI development cannot be established
from our results. Second, this study was not designed
with AKI as a primary endpoint and, as such, did not
collect sufficiently detailed urine output data; AKI was
only assessed retrospectively by changes in creatinine
[34]. Data were not available on renal replacement ther-
apy, which would have provided additional granularity to
the severity of AKI definition. Moreover, sepsis decreases
production of creatinine, limiting the use of changes in
creatinine levels as a marker of AKI [55]. A small pro-
portion of patients had insufficient sample volumes to
measure all biomarkers simultaneously. These measure-
ment issues may have resulted in non-differential mis-
classification, leading to an attenuation of associations
toward the null. Third, we cannot exclude the possibility
of reverse causality, wherein the damaged kidney itself
may release endothelial markers before creatinine rises,
and thus contributes to higher circulating levels of Ang-2
and lower circulating levels of Ang-1 [56]. Lastly, the sub-
jects included in this study are all recruited from a single
hospital and were all Caucasian, and this may limit the
ability to more broadly interpret our results. We did, how-
ever, include subjects transferred from outside hospitals in
the analyses and adjustment for this factor did not modify
the associations with poor outcome.
Conclusions
In conclusion, endothelial and inflammatory markers were
significantly associated with AKI among patients in critical
care. Further studies are needed to investigate the prog-
nostic value of these biomarkers and to potentially identify
interventions that modify these biomarkers.
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Additional file 1: Pairwise correlation matrix of endothelial and
inflammatory biomarkers. Pearson’s correlation coefficient (ρ) was used to
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Additional file 2: Associations of biomarkers with AKI (Stage 2–3 versus
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Additional file 3: Associations of biomarkers with AKI (any stage) after
exclusion of 173 patients with AKI within the first 24 h of admission. We
performed a secondary analysis to evaluate temporality issues and the
potential of reverse causality, in which we repeated examination of the
association of biomarkers with the AKI endpoint after exclusion of patients
with AKI events occurring within the first 24 h of admission. (DOCX 15 kb)
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